Climb Bio (CLYM)

• Market cap: $418M
• 1 day: -1.46%
• 5 days: -4.16%
• 1 month: 25.9%
• 3 months: 84.99%
• 6 months: 337.5%
• Year to date: 133.33%
• 1 year: 594.44%
• 5 years: -44.97%
• 10 years: -44.97%
• Sector: Healthcare
• Industry: Biotechnology

About: Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.

Employees: 29